ISBN: Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relative effect Anticipated absolute effects Risk with Placebo Risk difference with ARB (95% CI) d Unable to calculate as there were zero events in both arms Table 63: ARB high dose versus low dose (CKD class 3a/b) Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relative effect Anticipated absolute effects Risk with low dose Risk difference with ARB high dose (95% CI) Combined outcome: death or HF hospitalisation 945 VERY LOWa,b due to risk of bias, indirectness (from 53 fewer to 36 more) a Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias b Downgraded 1 increment due to indirectness as outcome was compound rather than numbers of admissions Table 64: Beta-blocker versus placebo (CKD stages 3-4) Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relative effect Anticipated absolute effects Risk with Placebo Risk difference with Beta-blocker (95% CI) All-cause mortality - CKD class 3a 1645 LOWb due to risk of bias Estimatea (from 5 fewer to 30 fewer) All-cause mortality - CKD class 3b-4 958 HR 0.55 Estimatea Treating Heart Failure Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. 